Bimatoprost (scalp)

The same prostamide analogue sold as Latisse for eyelash hypotrichosis and as Lumigan for glaucoma. Eyelash growth was first noticed as a side effect in glaucoma patients, which is why Allergan spent six years asking whether it would do the same on a balding scalp.

A useful negative: over three Phase 2 trials Allergan posted results on the registry but never published them, and in both trials that carried a minoxidil comparator, minoxidil outperformed every bimatoprost arm: +21.9 terminal hairs/cm² against the best bimatoprost arm's +13.1 in the 2011 men's study, +13.6 against +4.3 in the women's. No p-values were posted, so read those as arm means rather than a formal comparison. Allergan's last scalp study, a pharmacokinetic Phase 1, was terminated in 2017 without a stated reason and the company has registered nothing on the scalp since; no sponsor has ever announced the programme ended.

1. June 2011
   Phase 1→Phase 2

   First Phase 2 trial on record: NCT01325337 — Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

   ClinicalTrials.gov ↗
2. October 2010
   Phase 1

   First Phase 1 trial on record: NCT01189279 — Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

   ClinicalTrials.gov ↗

• NCT01904721Phase 2Completed

  A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

  Allergan · n=244 · August 2013

• NCT01325337Phase 2Completed

  Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

  Allergan · n=307 · June 2011

• NCT01325350Phase 2Completed

  Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

  Allergan · n=306 · June 2011

• NCT01189279Phase 1Completed

  Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

  Allergan · n=42 · October 2010

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

• Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (Phase 1, terminated 2017) — ClinicalTrials.gov
• Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss — ClinicalTrials.gov
• A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) — ClinicalTrials.gov
• Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia — ClinicalTrials.gov
• Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia — ClinicalTrials.gov
• Local Pharmacokinetics and Tolerability of Topically-Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia — Peer-reviewed, August 2026
• LATISSE (bimatoprost ophthalmic solution) 0.03%, prescribing information — Regulator filing, December 2008

Other programmes in the register with the same mechanism: Prostaglandin.

• DLQ-01 (latanoprost)Phase 1/2DermaLiq Therapeutics
• SetipiprantDiscontinuedAbbVie